Phase I/II – Other

632 trials 274 recruiting

Filter these 632 trials by condition, country, sponsor and more.

Open in Search →

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimum… Ended

2023-509061-20-00 Advanced solid tumors 2018-11-22
Durvalumab (MEDI4736 ) plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity: a window of opportunity… Ended

2024-511511-25-00 Resectable, locally advanced squamous cell carcinoma of 2018-10-12
A Phase I/II Randomized Study Evaluating if the study drug Alpha1H is effective and safe in comparison to placebo in adult patients with bla… Ended

2024-514628-17-00 Non-muscle invasive bladder cancer awaiting transurethr 2018-05-21
A Study to Evaluate Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Non-Small Cell Lu… Ended

2023-504038-23-00 Metastatic non-small cell lung cancer (NSCLC) 2018-05-10
A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP) Ended

2023-509397-39-00 Immune Thrombocytopenia 2018-03-20
Treatment of refractory Crohn's disease lesions by local injection of mesenchymal stem cells Ended

2024-514033-37-00 Crohn's Disease 2018-03-01
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Duc… Ended

2024-511271-15-00 Pancreatic ductal adenocarcinoma (PDAC) 2017-11-23
ABIMMUNE: A Phase I/II study evaluating the safety and clinical activity of anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) a… Ended

2024-514920-18-00 Metastatic squamous cell carcinoma of head and neck, lu 2017-06-20
A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab (… Ended

2024-515000-39-00 Recurrent glioblastoma. 2017-01-17
A trial of BMS-986012 in combination with chemotherapy for small cell lung cancer Ended

2024-511824-15-00 Extensive-Stage Small Cell Lung Cancer 2016-10-18
ROLLOVER STUDY FOR TAZEMETOSTAT Ended

2023-510553-41-00 Subjects will receive tazemetostat as dictated in their 2016-08-29
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination with Irinotecan in Pretreated Patien… Ended

2024-515394-10-00 Selected Advanced Solid Tumors 2016-04-26
A phase I/II trial of Obinutuzumab, ABT-199 (GDC-0199) plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma patients (OAsIs) Ended

2024-516750-21-00 Patients with relapsed / refractory Mantle Cell Lymphom 2015-10-14
Combined antitumor therapy with ex vivo manipulated dendritic cells producing interleukin-12 in children, adolescents and young adults with … Ended

2024-516613-21-00 Progressive, recurrent or primarily metastatic high-ris 2015-09-10
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Ended

2023-508067-70-00 Neoplasms by site 2015-04-15
ROMIDEPSIN IN COMBINATION WITH CHOEP AS FIRST LINE TREATMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN YOUNG PATIENTS WITH NODAL PER… Ended

2024-511639-83-00 Anaplastic Large T-cell Lymphoma ALK negative 2014-09-01
CheckMate 032:CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 032 Ended

2024-516540-25-00 Advanced or metastatic solid tumors: 1) Triple Negative 2013-12-11
A safety and efficacy extension of study HGT-MLD-070 in Children with Metachromatic Leukodystrophy recieving enzyme (HGT-1110) replacement b… Ended

2024-514403-34-00 Late Metachromatic Leukodystrophy (MLD) 2012-10-10
Hematopoietic stem cell gene therapy study Ended

2024-515253-25-00 Metachromatic Leukodystrophy (MLD) 2010-04-08
A Phase II Study of Dasatinib in Children and Adolescents with Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolera… Ended

2024-510784-36-00 Children and Adolescents with Newly Diagnosed Chronic P 2009-04-27
Phase 1 study of NG-350A plus pembrolizumab in metastatic or advanced epithelial tumours (FORTIFY) Ended

2023-503457-35-00 Epithelial tumours
Trail aiming to assess the safety and clinical activity of bemarituzumab + bevacizumab in advanced/metastatic gynecological cancer overexpre… Ended

2024-516724-33-00 Advanced/metastatic gynecological cancer overexpressing
C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People … Ended

2022-502822-41-00 Relapsed/Refractory Diffuse Large B Cell Lymphoma
Phase 1/2 Study of Belzutifan Plus Palbociclib Versus Belzutifan in Advanced Renal Cell Carcinoma (RCC) Ended

2023-504963-17-00 Advanced ccRCC